Cooperative Agreement UG3CA290443
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $462K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Arizona, USA
Similar Awards
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to define the mechanisms by which immune checkpoint inhibitor-associated bacteria modulate tumor immunity in cancer, particularly melanoma. The University of Pittsburgh will receive $636,222 over the award period of April 1, 2025 to March 31, 2030. The key focus of this research is to understand how microbial-derived aryl hydrocarbon receptor (AhR) ligands...
- This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $531,693.00 to the University of Southern California to conduct research aimed at improving immunotherapy treatments for breast cancer. The project will develop a computational model to understand the interactions between breast tumors and the immune system, with the goal of identifying new strategies to enhance the efficacy of immunotherapies. Key activities include...
- This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,732,297 to the University of Arizona to develop a novel non-invasive optical imaging approach for assessing skin lesions at multiple scales. The project aims to address limitations in current imaging techniques by utilizing synthetic waves to enable deeper optical imaging within highly scattering skin tissue. The 2-year project period runs from...
- This $746,572 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to discover and characterize the germline genetic mechanisms underlying cutaneous immune-related adverse events (CIRAEs) in cancer patients receiving immune checkpoint inhibitor (ICI) therapy. The research will involve analyzing germline genetic data from over...
- This Project Grant award of $176,712.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh, supports research on immunosurveillance mechanisms that eliminate pre-cancerous cells prior to the formation of malignancies. The primary objective is to investigate how tumor-derived heat shock proteins (HSPs) engage the CD91 receptor on antigen-presenting cells, leading to priming of T cell responses against emerging tumors. This research...
- This Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), aims to investigate the potential of a de novo dietary compound called Sumiki's Acid (SKA) as an immunomodulator for cancer immunoprevention. The $113,203 award, granted on August 1, 2025, will support research to determine SKA's ability to enhance natural killer (NK) cell activation and cytotoxicity against cancer cells, as well as evaluate its cancer-preventive effects in mouse models. The...
- This $575,051 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the University of Arizona Cancer Center (UACC) in enhancing its NCI-funded clinical research enterprise over a 5-year period from September 1, 2025 to August 31, 2030. The key objectives are to grow the breadth of the UACC's clinical trial portfolio to better serve its diverse patient population, increase accruals to interventional treatment trials (especially NCI-sponsored...
- This Cooperative Agreement award, valued at $704,622.00, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Mayo Clinic Arizona, a child entity of Mayo Collaborative Services, Inc. The award supports preclinical studies on the immunoprevention of multiple myeloma, a type of blood cancer. The research aims to develop faithful, immunocompetent mouse models that can recapitulate the progression from smoldering multiple myeloma to symptomatic multiple...
- This federal Project Grant award of $443,564 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to develop a novel cancer vaccination platform using engineered skin commensal bacteria. The primary objective is to leverage a prevalent skin bacterium, Staphylococcus epidermidis, to stimulate tumor-specific T cell immunity and enhance cancer immunotherapy. The research aims to overcome barriers in genetic engineering of clinically relevant skin...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...